Comparison of GAS5 expression levels in MG patients and healthy controls showed that GAS5 expression levels were significantly increased after proper treatment (cholinesterase inhibitor treatment), indicating that GAS5 expression may serve as an indicator of treatment outcomes of MG. The gene discussed is BCHE; the disease is myasthenia gravis.